The goal of this study was to evaluate the presence of cytotoxic T-lymphocytes and their relation to microglial activation and tau pathology load, focusing on early vulnerable regions, the SN and MBT, in patients with PSP or PD and in non-diseased controls (CO). The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.